Arana files IND
By Dylan Bushell-Embling
Tuesday, 30 September, 2008
Tuesday, 30 September, 2008
Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.
As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.
Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.
Related News
Maternal diet doesn't affect baby's food allergy risk
Higher maternal consumption of egg and peanut during pregnancy and breastfeeding does not protect...
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
